Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Total Debt (2016 - 2025)

Historic Total Debt for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $570.2 million.

  • Collegium Pharmaceutical's Total Debt fell 954.04% to $570.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $570.2 million, marking a year-over-year decrease of 954.04%. This contributed to the annual value of $615.3 million for FY2024, which is 5191.26% up from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Total Debt is $570.2 million, which was down 954.04% from $585.2 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Total Debt high stood at $630.3 million for Q3 2024, and its period low was $110.0 million during Q4 2021.
  • Moreover, its 5-year median value for Total Debt was $537.1 million (2023), whereas its average is $444.8 million.
  • Per our database at Business Quant, Collegium Pharmaceutical's Total Debt skyrocketed by 40907.39% in 2022 and then tumbled by 3589.66% in 2024.
  • Over the past 5 years, Collegium Pharmaceutical's Total Debt (Quarter) stood at $110.0 million in 2021, then soared by 409.07% to $560.1 million in 2022, then fell by 27.68% to $405.0 million in 2023, then surged by 51.91% to $615.3 million in 2024, then fell by 7.34% to $570.2 million in 2025.
  • Its last three reported values are $570.2 million in Q3 2025, $585.2 million for Q2 2025, and $600.3 million during Q1 2025.